LAURA Trial Part 1

from Lung Cancer Considered Hosted by IASLC

Lung Cancer Considered host Dr. Narjust Florez and Dr. Suresh Ramalingam discuss the recent FDA approval of osimertinib after chemo-radiation in EGFR positive NSCLC. The approval was based, in part, on the results of the LAURA trial, which was presented at the 2024 ASCO Annual Meeting. Guest: Dr. Suresh Ramalingam is the Executive Director, Winship Cancer Institute of Emory University, the Roberto C. Goizueta Distinguished Chair for Cancer Research, and a professor of medicine at Emory University School of Medicine. He is also the editor in chief for the Cancer Journal.

Episode details come from the podcast's RSS feed.

Embed this episode

Attribution link and audio player

Ready to play

LAURA Trial Part 1

0:00 27:05

No transcript yet.

Requests help us decide what to transcribe next.

Share this episode

Similar podcasts

Lung Cancer Update for Nurses Dr Neil Love Featuring one-on-one interviews conducted by Dr Neil Love with national lung cancer clinical investigators and oncology nurses, this series provides practicing clinicians including nurses and nurse practitioners with valuable information and current clinical management strategies that can be applied to optimize patient care.

Frequently asked questions

How long is this episode of Lung Cancer Considered?

This episode is 27 minutes long.

When was this Lung Cancer Considered episode published?

This episode was published on November 29, 2024.

Can I download this Lung Cancer Considered episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.